Vantis Vascular, Inc. has completed the Series B-1 preferred financing round, raising $10 million and overall funding reached $30 million. Some investors include high-net-worth individuals and NIH grants.
The founder and the CEO of Vantis Vascular, Jason Turner, noted this achievement meaningfully: “This funding will help us proceed with product dev, expand our team, and start the US comm of CrossFAST Advanced Delivery System for intricate, high-risk PCI interventions.”
Transforming Interventional Procedures CrossFAST
The CrossFAST Advanced Delivery System is an innovative step in dealing with tricky coronary and peripheral cases. It is actually the microcatheter system involving two monorails that are intended to be used in high-risk procedures.
Unlike conventional guide extension catheters that have the disadvantage of vessel trauma and damage on previous stents, CrossFAST combines a microcatheter that eliminates this risk through a smooth transition.
The system utilizes DuoPRO Interlocking Technology, which enables it to connect the microcatheter and the outer delivery catheter so that it can slide together as one. This improves usability and maneuverability in complex anatomies, which is a major drawback of current technologies.
Strategies for Limited and Full Market Release
Mr. Gary McCord of Vantis Vascular stated his intention to conduct a limited market release of the CrossFAST System in the US. CrossFAST System will help physicians to work more safely with multiple anatomical structures. It also enhances the delivery of the necessary therapies, according to McCord.
The CrossFAST System is projected to hit the market fully by 2025. As a result, this new answer is likely to revolutionize the paradigm of interventional cardiology and vascular operations.
